Navigation Links
YM sees nimotuzumab license unaffected by civil claim against licensor
Date:3/2/2010

l molecule vascular disruptive agent in clinical development. Data from both the JAK and VDA trials are also expected during 2010. The oral availability of the VDA differentiates it importantly from most or all of the other VDAs in development and the JAK 1/2-targeting drug additionally enjoys advantages over other members of this class in development. Recent licenses by development companies to multinational pharmaceutical companies for VDA and JAK-targeting drugs are evidence of high interest from that industry for agents in these classes and the substantial sums paid provide benchmarks against which drugs in development may be measured.

About YM BioSciences

YM BioSciences Inc. is a life sciences product development. Together with the products from the merged Australian company, Cytopia Ltd (now YM Australia), the Company is currently developing four late-stage products: nimotuzumab, an EGFR-targeting Affinity-Optimized Antibody(TM); CYT 387, a JAK 1/2 small molecule inhibitor, CYT 997, a potent, vascular disrupting agent and AeroLEF(R), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization.

Nimotuzum
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA
2. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING
3. YM BIOSCIENCES REPORTS POSITIVE NIMOTUZUMAB FOUR-YEAR SURVIVAL DATA PRESENTED AT ASTRO 2009
4. YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG
5. YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO
6. YM BIOSCIENCES USA RECEIVES CLEARANCE FROM US TREASURY DEPARTMENT TO EXTEND CLINICAL PROGRAM FOR NIMOTUZUMAB
7. YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB
8. NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS
9. YM BIOSCIENCES ANNOUNCES RESULTS OF RANDOMIZED NIMOTUZUMAB STUDY TO BE PRESENTED IN A POSTER AT ASCO ANNUAL MEETING
10. YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER
11. YM BIOSCIENCES NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... military conflicts in Iraq and Afghanistan, more than 300,000 ... brain injury caused by exposure to bomb blasts ... IEDs. Symptoms of traumatic brain injury can range from ... more severe impairments in memory and cognition. , ... the critical importance and complexity of this problem, and ...
(Date:9/29/2014)... challenges in food security, emerging diseases and biodiversity ... published online in Science Express that ... of Arizona College of Agriculture and Life Sciences. ... of nine scientists has reviewed progress in addressing ... and environmental management using approaches that consider evolutionary ...
(Date:9/29/2014)... Transparency Market Research, in its report titled ‘Peptide ... Application - Cancer, Metabolic, CVS, CNS & others, by ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast, ... market was worth US$14.1 billion in 2011 and is ... 8.7% CAGR. , The two main types of peptide ...
(Date:9/29/2014)... SQI Diagnostics Inc. (TSX-V: SQD) (OTCQX: SQIDF), a life ... products for advanced microarray diagnostics, is pleased to announce ... of the Board of Directors of SQI, replacing ... as a Director on the Board and will continue ... "We are very pleased to have Mr. Winkley assume ...
Breaking Biology Technology:Modeling shockwaves through the brain 2Modeling shockwaves through the brain 3Modeling shockwaves through the brain 4Evolutionary biology: It's not just for textbooks anymore 2Evolutionary biology: It's not just for textbooks anymore 3Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 2Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 3SQI Diagnostics Announces New Chairman of Board of Directors 2
... CHARENTON-LE-PONT, France, January 10 Essilor,of America, Essilor ... in the United States with the acquisition,of Interstate ... independent,laboratories. Interstate,s two laboratories in Mansfield, Ohio and,Indianapolis, ... The,company has full-year sales of US$26 million and ...
... of,Maryland, Baltimore (UMB) BioPark today announced that Gliknik ... in the BioInnovation,Center, located in UMB BioPark,s Building ... for autoimmune diseases,and cancer, the foundation of which ... Professor and Chairman of the Department of,Otorhinolarynogology, University ...
... 9 Burrill Merchant Banking acted as,exclusive financial ... partnering of bilastine with the Menarini Group (Italy). ... bilastine rights in Europe,and other regions to Menarini ... is a new highly selective H1 antihistamine for ...
Cached Biology Technology:University of Maryland, Baltimore BioPark Signs Gliknik Inc. as First Tenant in Its BioInnovation Center in Building Two 2Burrill Merchant Banking Advises Faes Farma on Bilastine Licensing Agreement 2
(Date:9/29/2014)... PULLMAN, Wash. Scientists at Washington State University ... specifically, Granny Smith apples may help prevent ... be the first to assess these compounds in ... in October,s print edition of the journal ... apples are a good source of these nondigestible ...
(Date:9/29/2014)... have found compounds that boost liver detoxification enzymes nearly ... placethe crushed seeds left after oil extraction from an ... compounds in Camelina sativa seed, also known ... phytochemicals that work together synergistically far better than they ... supplement because its bioactive ingredients increase the liver,s ability ...
(Date:9/29/2014)... is often deemed inaccessible or esoteric. Yet in the ... in our daily lives and a decisive role in ... behind the scenes. , UC Santa Barbara,s Paul Atzberger, ... assistant professor of mechanical engineering, often works in areas ... research published in the Proceedings of the National ...
Breaking Biology News(10 mins):An apple a day could keep obesity away 2New way to detox? 'Gold of Pleasure' oilseed boosts liver detoxification enzymes 2At the interface of math and science 2At the interface of math and science 3At the interface of math and science 4
... institutions, led by Stanford University and Brown University, have ... federal funding to learn both how the brain and ... can be done to encourage recovery from injury. ... developing the neurotechnology to ultimately enable an entirely new ...
... find answers about ovarian cancer, researchers now have something to ... been using the chicken as a model to study this ... with flaxseed decreases severity of ovarian cancer and increases survival ... of alpha-linolenic acid, one type of omega-3 fatty acid. Several ...
... normally infect rodents, but they are also infectious for ... symptoms in humans. Most importantly, these viruses have an ... any damage to healthy tissue. Therefore, scientists in the ... German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have been ...
Cached Biology News:New Stanford-led program aims to produce insights into brain injury, recovery 2New Stanford-led program aims to produce insights into brain injury, recovery 3Flaxseed-fed chickens shed light on ovarian cancer 2Flaxseed-fed chickens shed light on ovarian cancer 3Viruses against cancer 2Viruses against cancer 3